Nanjing Legend Biotech CAR-T Patent, GPC2 Cancer Immunotherapy

Tue, 21 Apr 2026 14:20:15 +0000
Intellectual Property

The USPTO granted Patent US12606635B2 to Nanjing Legend Biotech Co., Ltd. covering GPC2-specific antibodies, antigen binding fragments, and chimeric antigen receptor (CAR) constructs for cancer immunotherapy. The patent encompasses T cells engineered with the disclosed CAR constructs. The application (No. 17910608) was filed March 12, 2021, and contains 19 claims.